Rapport Therapeutics, Inc. announced on September 9, 2025, that it has entered into an Underwriting Agreement for a public offering of 9,615,385 shares at $26.00 each, aiming to raise approximately $234.7 million for clinical trials and general corporate purposes. The offering is expected to close around September 11, 2025.